Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Rivera, Luis; Biswal, Shibadas; Sáez‐Llorens, Xavier; Reynales, Humberto; López‐Medina, Eduardo; Borja-Tabora, Charissa; Bravo, Lulu; Sirivichayakul, Chukiat; Kosalaraksa, Pope; Martinez Vargas, Luis; Yu, Delia; Watanaveeradej, Veerachai; Espinoza, Félix; Dietze, Reynaldo; Fernando, LakKumar; Wickramasinghe, Pujitha; Duarte Moreira, Edson; D. Fernando, Asvini; Gunasekera, Dulanie; Giovanni Luz, Kléber; Venâncioda Cunha, Rivaldo; Rauscher, Martina; Zent, Olaf; Liu, Mengya; Hoffman, Elaine; Lefevre, Inge; Tricou, Vianney; Wallace, Derek; Alera, MariaTheresa; Borkowski, Astrid

doi:10.1093/cid/ciab864

Public

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Published in Clinical Infectious Diseases • Sep 30, 2021

Authors:

Luis Rivera

Shibadas Biswal

Xavier Sáez‐Llorens

Abstract

BACKGROUND: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and seropositive participants and that its performance va...

Subject

Medicine

Dengue fever

Dengue vaccine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!